Navigation Links
Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012

MALVERN, Pa., Nov. 1, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the third quarter 2012 on Wednesday, November 7, 2012 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter 2012.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 10 a.m. ET on Wednesday, November 7, 2012.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Wednesday, November 7, 2012.  A question and answer session will follow the presentation.


Mr. Adrian Adams, Chief Executive Officer and President, will host the conference call.Conference call details:Date:Wednesday, November 7, 2012Time:10:00 a.m. ETDial-in (U.S.):(888) 895-5271 Dial-in (International):(847) 619-6547Web cast: Passcode:AUXILIUMTo access an audio replay of the call:Access number (U.S.):(888) 843-7419Access number (International):(630) 652-3042Replay Passcode #:33615316About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. GSK co-promotes Testim with Auxilium in the U.S.  Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  An sBLA for XIAFLEX for the treatment of Peyronie's disease is expected to be submitted to the FDA by year end 2012.  Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for CCH. For additional information, visit

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the third quarter 2012 results; and products in development for Peyronie's disease, including the expected filing of an sBLA, Frozen Shoulder syndrome and cellulite.  Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.  A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, which are on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Auxilium undertakes no obligation to update publicly any forward-looking statement.AUXILIUM CONTACTS: James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., IR  Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.(484) 321-5900


SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
2. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
3. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
4. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
9. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
10. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
11. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
Post Your Comments:
(Date:11/24/2015)... , Nov. 25, 2015 WuXi PharmaTech (Cayman) ... a leading open-access R&D capability and technology platform company ... operations in China and ... at an extraordinary general meeting of shareholders held today, ... to authorize and approve the previously announced agreement and ...
(Date:11/24/2015)... , Nov. 24, 2015  Natera, ... in non-invasive genetic testing and the analysis ... it will present at the 27 th ... December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., ... financial results, business activities and financial outlook. ...
(Date:11/24/2015)... 24, 2015  In the pharmaceutical industry, companies want ... to quickly uncover new insights, tactics and strategies that ... --> However, organizations often find it ... and ensure that all rules and regulations are met ... major barrier to efficiently launching market research projects is ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... their knowledge and experiences at a live taping of the next CURE ... the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel & Conference ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... With Thanksgiving ... Insurance is sharing safety tips to help protect your family and vehicle. , According ... around the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Bibliomotion ... and Detroit Taught Me about Reinvention and Diversity by Nancy M. Schlichting, ... suffer, with hospitals failing to adequately address the needs of patients and their families, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... All her life, Don Peck’s mother wondered if ... obituary said she might have been. After a 25-year search for information, Don and ... whom she shared a last name. Turns out, it was Don’s father who was ...
Breaking Medicine News(10 mins):